Endpoint innovation and success stories are driving a surge in renal disease drug development

Plus CureVac hiring Novartis’ Mendila, adding antigen discovery platform via Frame takeout, and updates from Aldeyra, Astellas, PineTree and more

Plus Alphabet launches digital biology venture, IO Biotech’s IPO, setbacks for Deciphera, Calithera and more 

Crinetics spins out radiotherapeutics company, IO Biotech, Calithera, Sana and more

In FDA’s first approval of a new therapy for chronic weight management since 2014, the agency approved GLP-1 analog Wegovy semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO). The

The $125M up front will fuel development of the early stage IRAK program that Rigel has opted to keep

After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to fund the cancer therapy’s registrational trial, slated for 2021. The funding will also

Sorrento Therapeutics Inc. (NASDAQ:SRNE) terminated Jiong Shao as EVP and CFO. He is succeeded as CFO by Najjam Asghar, who is the company’s chief accounting officer. Sorrento did not

Kronos buys Gilead’s portfolio of SYK inhibitors, carrying the preclinical cancer play to the cusp of Phase III